Info Sheet , Human ADME , Radiosynthesis , Clinical Pharmacology

Human ADME Capabilities

Overview

With over 30 years’ experience as a world leading provider of human ADME 14C radiolabeled studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings.

Download

Your challenges. Our solutions.

Learn more about our expertise in human ADME studies.

Contact Us
Quotient Sciences Logo
Human ADME, Regulatory

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read More

More about our human ADME capabilities

Browse More
Scientific Poster, Iain Shaw, Human ADME, Clinical Pharmacology
ISSX 2022: A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes
14 December 2022
Download Now
Whitepaper, Human ADME
Synthesis-to-Clinic®: A streamlined approach to 14C human ADME studies
Download Now
Browse More
Get in touch
Humanity can't afford to wait, so neither can we.
Let's talk